Hiroyuki et al., 2001 - Google Patents
Efficacy and safety of Touchi extract, an α-glucosidase inhibitor derived from fermented soybeans, in non-insulin-dependent diabetic mellitusHiroyuki et al., 2001
- Document ID
- 154455030887964653
- Author
- Hiroyuki F
- Tomohide Y
- Kazunori O
- Publication year
- Publication venue
- The Journal of nutritional biochemistry
External Links
Snippet
The water-extracted Touchi, a traditional Chinese food, exerted a strong inhibitory activity against rat intestinal α-glucosidase in foodstuffs. In borderline and developed diabetic subjects, 0.3 g of Touchi-extract (TE) significantly inhibited postprandial blood glucose …
- 206010067584 Type 1 diabetes mellitus 0 title abstract description 5
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Micro-organisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hiroyuki et al. | Efficacy and safety of Touchi extract, an α-glucosidase inhibitor derived from fermented soybeans, in non-insulin-dependent diabetic mellitus | |
| Fujita et al. | Long-term ingestion of a fermented soybean-derived Touchi-extract with α-glucosidase inhibitory activity is safe and effective in humans with borderline and mild type-2 diabetes | |
| Fujita et al. | Long-term ingestion of Touchi-extract, an α-glucosidase inhibitor, by borderline and mild type-2 diabetic subjects is safe and significantly reduces blood glucose levels | |
| Fujita et al. | Fermented soybean–derived water-soluble Touchi extract inhibits α-glucosidase and is antiglycemic in rats and humans after single oral treatments | |
| Vichayanrat et al. | Efficacy and safety of voglibose in comparison with acarbose in type 2 diabetic patients | |
| Hu et al. | Soy fiber improves weight loss and lipid profile in overweight and obese adults: a randomized controlled trial | |
| Fujita et al. | Antihypercholesterolemic effect of Chinese black tea extract in human subjects with borderline hypercholesterolemia | |
| CZ20013345A3 (en) | Medicament for treating diabetes mellitus | |
| CN101175416A (en) | A method and composition for nutritionally improving glucose control and insulin action | |
| Agrawal et al. | Effect of oyster mushroom on glycemia, lipid profile and quality of life in type 2 diabetic patients | |
| Ebrahimi-Mameghani et al. | TCF7L2-rs7903146 polymorphism modulates the effect of artichoke leaf extract supplementation on insulin resistance in metabolic syndrome: a randomized, double-blind, placebo-controlled trial | |
| US11896613B2 (en) | Functional food | |
| Chearskul et al. | Glycemic and lipid responses to glucomannan in Thais with type 2 diabetes mellitus | |
| Mohamed et al. | A randomized, placebo-controlled crossover study to evaluate postprandial glucometabolic effects of mulberry leaf extract, vitamin D, chromium, and fiber in people with type 2 diabetes | |
| Hosseinzadeh et al. | Brewer’s yeast improves blood pressure in type 2 diabetes mellitus | |
| Oba-Yamamoto et al. | Impact of low-starch high-fiber pasta on postprandial blood glucose | |
| Petchetti et al. | Nutriceuticals in cardiovascular disease: psyllium | |
| JP2019210269A (en) | Composition for treating diabetic disease | |
| Suthar et al. | Efficacy and safety of PDM011011 capsules as compared to metformin in subjects with type-2 diabetes mellitus: An open-label, randomized, active-controlled, multicentric, phase III study | |
| Fujita et al. | Efficacy and safety of Chinese black tea (Pu-Ehr) extract in healthy and hypercholesterolemic subjects | |
| GB2468629A (en) | Therapeutic uses of a composition comprising an amylase, a lipase and a protease | |
| US20090317371A1 (en) | Method, Composition, and Device, for the Treatment of Amylase Malfunctions / Inactivity in Association with Saccharides (Mainly Polysaccharides) Based Diseases | |
| US9192180B2 (en) | Nutritionally enhanced fraction from rice bran and method of lowering insulin resistance using same | |
| US20060280681A1 (en) | Food for testing life style-related diseases | |
| Maddox | Cinnamon in the treatment of Type II diabetes |